Stock AnalizDavita Inc. DVA
Misc Health and Biotechnology Services · data as of November 13, 2026
Davita Inc. (DVA) is a healthcare company listed in the US with a market value of about $11.0B. In the twelve months to September 30, 2026 it had revenue of $14.2B and net income of $920M, a net margin of 6.5%.
Its overall Stock Analiz score is 2.2 out of 5 (weak). The strongest part is value (5/5); the weakest is future growth (1/5).
Key numbers: a P/E of 12.9, a price to free cash flow of 8.5, 5-year revenue growth of 3% a year, a 5-year average ROIC of 12%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 98% above the current price.
Score: 2.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- Profitable 5 years in a row
- Positive free cash flow
Checks not passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
- ROE above 15%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.2B | $13.6B | $12.8B | $12.1B | $11.6B | $11.6B | $11.6B | $11.4B | $11.4B | $10.9B | $10.7B |
| Net income | $920M | $747M | $936M | $692M | $560M | $978M | $774M | $811M | $159M | $664M | $880M |
| Free cash flow | $1.3B | $1.3B | $1.5B | $1.5B | $961M | $1.3B | $1.3B | $1.3B | $785M | $1.0B | $1.1B |
| EPS (diluted) | $13.51 | $9.84 | $10.73 | $7.42 | $5.85 | $8.90 | $6.31 | $5.27 | $0.92 | $3.47 | $4.29 |
| Net margin | 6.5% | 5.5% | 7.3% | 5.7% | 4.8% | 8.4% | 6.7% | 7.1% | 1.4% | 6.1% | 8.2% |
| ROIC | — | 13.1% | 14.0% | 10.7% | 8.5% | 11.3% | 10.3% | 9.5% | 8.3% | 9.9% | 10.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $222.29, 27% above the current price; targets range from $165.00 to $287.00; the consensus rating is “Buy”; expected EPS is $14.70 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Davita’s P/E ratio?
About 12.9, based on the last twelve months of diluted earnings per share (forward P/E about 11.0).
Is Davita stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 98% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Davita pay a dividend?
Not currently.
Is Davita a good stock to buy?
We do not give buy or sell advice. Davita scores 2.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.